Zhou, Q., Almquist, D., Cho, B. C., Smit, E. F., Caglevic, C., Liikanen, I., Lugini, A., Dziadziuszko, R., Viqueira, B. R., Powell, S. F., Kunta, G., Ozyilkan, O., Prytuliak, S., Wang, L., Erman, M., Chen, D., Eiras, R., Ogino, A., Rojas, C. (2026). KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with KRAS G12C mutations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8679